Stopka Lab
Publications (dedicated to NPU=N or Biocev=B, international collaboration=I, collaboration with hospital=H, from group in Inst.131/from Detached group)
Differential requirements for Smarca5 expression during hematopoietic stem cell commitment. Turkova T, Kokavec J, Zikmund T, Dibus N, Pimkova K, Nemec D, Holeckova M, Ruskova L, Sedlacek R, Cermak L, Stopka T.Commun Biol. 2024 Feb 29;7(1):244. doi: 10.1038/s42003-024-05917-z. (IF 5.9) [PubMed] JCR/JCI Q1
Chromatin Remodeling Enzyme Snf2h Is Essential for Retinal Cell Proliferation and Photoreceptor Maintenance. Kuzelova A, Dupacova N, Antosova B, Sunny SS, Kozmik Z Jr., Paces J, Skoultchi AI, Stopka T, Kozmik Z. Cells. 2023; 12(7):1035. https://doi.org/10.3390/cells12071035 (IF 6.0) [PubMeb] JCR/JCI Q2
SILAC-IodoTMT for Assessment of the Cellular Proteome and Its Redox Status.Vajrychova M, Salovska B, Pimkova K, Fabrik I, Hodny Z. Methods Mol Biol. 2023;2603:259-268. doi: 10.1007/978-1-0716-2863-8_21. (IF N/A)[PubMed] (H, I, 131)
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Stopka T, Minařík L, Dusilková N, Pešta M, Kulvait V, Špaček M, Zemanová Z, Kalousová M, Jonášová A. Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2. (IF 12.8) [link] (H, 131) JCR/JCI Q1
Quantitative analysis of redox proteome reveals oxidation-sensitive protein thiols acting in fundamental processes of developmental hematopoiesis. Pimkova K, Jassinskaja M, Munita R, Ciesla M, Guzzi N, Cao Thi Ngoc P, Vajrychova M, Johansson E, Bellodi C, Hansson J. Redox Biology. Volume 53, July 2022, 102343. ISSN 2213-2317. https://doi.org/10.1016/j.redox.2022.102343. (IF 11.4) [link] (H, I, 131) JCR/JCI Q1
Peroxiredoxin 6 protects irradiated cells from oxidative stress and shapes their senescence-associated cytokine landscape.Salovska B, Kondelova A, Pimkova K, Liblova Z, Pribyl M, Fabrik I, Bartek J, Vajrychova M, Hodny Z. Redox Biol. 2022 Feb;49:102212. doi: 10.1016/j.redox.2021.102212. (IF 11.4) [link] (H, I, 131) JCR/JCI Q1
Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. Bašová P, Paszeková H, Minařík L, Dluhošová M, Burda P, Stopka T. International Journal of Molecular Sciences. 2022; 23(12):6729. https://doi.org/10.3390/ijms23126729. (IF 5.6) [link] (131) JCR Q1 / JCI Q2
Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas.Krsmanovic P, Mocikova H, Chramostova K, Klanova M, Trnkova M, Pesta M, Laslo P, Pytlik R, Stopka T, Trneny M, Pospisil V. Cancers. 2022; 14(9):2305. https://doi.org/10.3390/cancers14092305 (IF 5.2) [Web] (I, H, 131) JCR/JCI Q2
Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization. Thakur S, Cahais V, Turkova T, Zikmund T, Renard C, Stopka T, Korenjak M, Zavadil J. Cells 2022, 11,808. https://doi.org/10.3390/cells11050808 (IF 6.0) [PubMed] (I,131) JCR/JCI Q2
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Cells. 2022; 11(2):223. https://doi.org/10.3390/cells11020223. (IF 6.0) [PubMed] (131) JCR/JCI Q2
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T, Jonasova A, Bokorova R, Fuchs O, Stritesky J, Salovska B, Bartek J, Hodny Z. Mol Oncol. 2020;10.1002/1878-0261.12768. doi:10.1002/1878-0261.12768. (IF 6.603) [PubMed] (H, I, 131) JCR/JCI Q1
Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry. Minarik L, Vargova K, Dusilkova N, Kulvait V, Jonasova Am Kodet O, Stopka T. Folia Biol (Praha). 2020;66(1):1-6. (IF 0.906) [Pubmed] (H, 131) JCR/JCI Q4
Universal promoter scanning by Pol II during transcription initiation in Saccharomyces cerevisiae. Qiu C, Jin H, Vvedenskaya I, Llenas JA, Zhao T, Malik I, Visbisky AM, Schwartz SL, Cui P, Čabart P, Han KH, Lai W, Metz RP, Johnson CD, Sze SH, Pugh BF, Nickels BE & Kaplan, CD (2020). Genome biology, 21(1), 132. https://doi.org/10.1186/s13059-020-02040-0. (IF 10.806) [PubMed] (131) JCR/JCI Q1
Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. Zikmund T, Paszekova H, Kokavec J, Kerbs P, Thakur S, Turkova T, Tauchmanova P, Greif PA, Stopka T. Int J Mol Sci. 2020;21(6):E2073. Published 2020 Mar 18. doi:10.3390/ijms21062073. (IF 5.924) [PubMeb] (B, N, I, H, 131) JCR Q1 / JCI Q2
The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi A, Zhang Y. Genes Dev. 2020;34(3-4):166–178. doi:10.1101/gad.331157.119. (IF 8.990)[PubMed] (I, H) JCR/JCI Q1
Vajrychová M, Stráník J, Pimková K, Barman M, Kukla R, Zedníková P, Bolehovská R, Plíšková L, Hornychová H, Andrýs C, Tambor V, Lenčo J, Jacobsson B, Kacerovský M. Comprehensive proteomic investigation of infectious and inflammatory changes in late preterm prelabour rupture of membranes. Sci Rep. 2020 Oct 19;10(1):17696. doi: 10.1038/s41598-020-74756-9. (IF 3.998) [PubMed]
ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing β-Selection. Zikmund T, Kokavec J, Turkova T, Savvulidi F, Paszekova H, Vodenkova S, Sedlacek R, Skoultchi AI, Stopka T. J Immunol. 2019 Jun 15;202(12):3434-3446. doi: 10.4049/jimmunol.1801684. (IF 4.886) [PubMed](B, N, I, 131) JCR/JCI Q2
Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty. Skalicka P, Dudakova L, Palos M, Huna L, Evans CJ, Mahelkova G, Meliska M, Stopka T, Tuft S, Liskova P. Acta Ophthalmologica. In Press. (IF 3.362) [PubMed] (I, H, 131) JCR Q2 / JCI Q1
Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS. Minarik L, Zemanova Z, Kulvait V, Dluhosova M, Jonasova A and Stopka T. Ann Hematol Oncol. 2019; 6(1): 0000. (IF N/A) [PDF] (N, B, H, 131)
Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika – interim analýza. Stopka T, Minarik L, Kulvait V, Pesta M, Schaffartzikova A, Kislik G, Dusilkova N, Zemanova Z, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 7 / číslo 2 / listopad 2019. (131)
Akutní myeloidní leukémie - Novinky v diagnostice a léčbě. Stopka T. Event Report z EHA 2018. [PDF] (N, 131)
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086. (IF 7.570) [PubMed] (I, 131) JCR/JCI Q1
Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin±prednisone addition to lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, Michalova K, Zemanova Z. Leukemia Research 69 (2018) 12-17. 2018 March 27. https://doi.org/10.1016/j.leukres.2018.03.015 . (IF 2.066) [PDF] (H, 131) JCR/JCI Q3
1. interim analýza randomizované otevřené klinické studie GA-MDS/2013. Dusilkova N, Minarik L, Stopka T, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 6 / Číslo 1 / květen 2018. [PDF] (N, 131)
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. Polgarova K, Vargova K, Kulvait V, Dusilkova N, Minarik L, Zemanova Z, Pesta M, Jonasova A and Stopka T. Oncotarget. 2017 Dec 6. (IF 5.168) [PDF] (B, N, H, 131) JCR Q2
Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer. Basova P, Pesta M, Sochor M, Stopka T. Int J Mol Sci. 2017 Oct 10;18(10). pii: E2116. doi: 10.3390/ijms18102116. (IF 3.687) [PDF](B, N, H, 131) JCR Q1 / JCI Q2
Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas. Dusilkova N, Basova P, Polivka J, Kodet O, Kulvait V, Pesta M, Trneny M, Stopka T. Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136. (IF 3.687) [PDF] (B, N, H, 131) JCR Q1 / JCI Q2
MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T. Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. (IF 8.125) [PDF] (B, N, H, 131) JCR/JCI Q1
Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Oncogene. 2017 Jul 10. (IF 6.854) [PDF] (B, N, I, 131) JCR/JCI Q1
Využití detekce somatických mutací pro pacienty s cytopenií nejasného významu a u myelodysplastického syndromu. Stopka T. Myelodysplastic Syndrome NEWS. Ročník 5 / Číslo 1 / květen 2017. [PDF] (N, 131)
The ISWI ATPase Smarca (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. Kokavec J, Zikmund T, Savvulidi F, Kulvait V, Edelmann W, Skoultchi AI, Stopka T. Stem Cells. 2017 Mar 9. doi: 10.1002/stem.2604. (IF 5.587) [PDF] (B, N, I, 131) JCR/JCI Q1
Somatické mutace u myelodysplastického syndromu a jejich klinické využití. Tomáš Stopka. Myelodysplastic Syndrome NEWS. Ročník 4 / Číslo 2 / listopad 2016 [PDF] (N, 131)
Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: evidence for co-repressor functions. DN Papageorgiou, E Karkoulia, A Amaral-Psarris, P Burda, K Kolodziej, JA Demmers, J Bungert, T Stopka, J Strouboulis. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, accepted (IF: 5.018) [PDF] (N, B, I, H, 131) JCR Q1 / JCI Q2
Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T. Blood Cancer J. 2016 Sep 23;6(9):e475. (IF 6.126) [PDF] (N, B, I, H, 131) JCR/JCI Q1
GATA-1 inhibits PU.1 gene via DNA and histone H3K9 Methylation of its Distal Enhancer in Erythroleukemia. P Burda, J. Vargova, N Curik, C Salek, G Papadopoulos, J Strouboulis and T. Stopka. PLoS One, 2016 Mar 24;11(3):e0152234. (IF 2.806) [PDF] (B, N, I, H, 131) JCR Q2 / JCI Q1
Chromatin remodeling enzyme Snf2h/Smarca5 regulates embryonic lens differentiation and denucleation. Shuying He, Saima Limi, Rebecca S. McGreal, Qing Xie, Lisa A. Brennan, Wanda Lee Kantorow, Juraj Kokavec, Romit Majumdar, Harry Hou, Jr, Winfried Edelmann, Wei Liu, Ruth Ashery-Padan, Jiri Zavadil, Marc Kantorow, Arthur Skoultchi, Tomas Stopka, and Ales Cvekl. Development. 2016 Jun 1;143(11):1937-47. (IF 5.843) [PDF] (B, N, I, 131) JCR/JCI Q1